Table 1 Patient characteristicsa
Site of primary (P) and metastases (M) | Prior treatment | Morphology | Multifocal (MF) Tumour size Mitotic index (MI) | KIT/PDGFRA mutation status | Other clinical features of particular relevance | |
|---|---|---|---|---|---|---|
Patient A | P – Stomach M – Liver | R2 surgery, imatinib | Epithelioid | MF- Yes 11.0 cm MI >10/50 HPF | Both WT | GI bleeding, palpable tumour |
Patient B | P – Stomach M– Liver – IP cavity | R2 surgery then imatinib after recurrence | Mixed | MF –no 3.0 cm MI 6/50 HPF | Both WT | GI bleeding |
Patient C | P – Stomach M – Liver – IP Cavity | R2 surgery, imatinib | Epithellioid | MF – yes 6.0 cm MI NA | Both WT | GI bleeding |
Patient D | P – Stomach – IP cavity | R2 surgery, imatinib | Mixed | MF – yes 11.0 cm MI 05/50 HPF | Both WT | GI bleeding |
Patient E | P – Stomach M – Omentum | Surgery, imatinib at first progression | Mixed | MF – Yes 7.0 cm 10/50 HPF | Both WT | GI bleeding from tumour |
Patient F | P – Stomach M – None | Surgery at diagnosis and recurrence | Epithelioid | MF – No 4.5 cm MI 50//10 HPF | Both WT | Pain, nausea, vomiting, GI bleeding from tumour |
Patient G | P – Stomach M – None | Surgery | Mixed | MF – No 10.0 cm MI 17/50 HPF | Both WT | Abdominal pain |
Patient H | P – Stomach M – Liver – IP cavity | Imatinib | Spindle | MF-yes NA MI 1/20 HP | Both WT | Marked anaemia |
Patient I | P – Stomach M – Liver | Surgery, imatinib | Spindle | MF-no 3 cm MI 20/50 HPF | Both WT | Melaena and anaemia |